Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2249–2259. doi: 10.1158/1535-7163.MCT-15-0429

Table I. Combination indices for studies testing the combination of either PKC412+CGM097 or AC220+CGM097 in the presence of RPMI+10% FBS, HS-5 SCM (90%), or HS27a SCM (90%).

All studies are representative of two independent studies for which similar results were observed.

Combination Indices
Condition ED25 ED50 ED75 ED90
RPMI+10% FBS (PKC412+CGM097) 0.78574 0.73627 0.69571 0.66305
HS-5 SCM (PKC412+CGM097) 0.74431 0.63563 0.54300 0.46402
HS27a SCM (PKC412+CGM097) 0.68059 0.60298 0.54904 0.51249
RPMI+10%FBS (AC220+CGM097) 0.80274 0.81577 0.88637 1.03173
HS-5 SCM (AC220+CGM097) 0.70215 0.82179 0.99324 1.24610
HS27a SCM (AC220+CGM097) 0.43172 0.57599 0.77412 1.04741